Medtronic (MDT) Stock Forecast & Price Target

Medtronic's stock outlook is bolstered by a stable growth trajectory in the global cardiac rhythm management (CRM) market, maintaining a 6% growth rate, alongside a noteworthy acceleration in Cardiac Ablation Solutions, which rose to 80% growth driven by the Affera Sphere-9. The company experienced organic revenue growth improvement from 5.5% to 6.0% in F3Q26, fueled by advancements in its Cardiovascular and Diabetes segments, indicating the potential for a robust product cycle ahead. Additionally, upcoming drivers for growth include favorable sales of new medical technologies, enhanced profit margins, and positive currency influences, coupled with the integration of Scientia Vascular’s products expected to leverage Medtronic’s larger sales force and international reach.

Medtronic's stock outlook appears negative due to a decline in market share across key segments, including a 20 basis point drop in the spine market and a 30 basis point decrease in the neuromodulation market year-over-year. Operating margins have also shown a significant decline, with non-GAAP operating margins decreasing by 210 basis points compared to the previous year, driven by unfavorable product mix and costs that outpaced any operational efficiencies. Additionally, forecasts predict revenue growth may slow to below 5%, influenced by disappointing new product launches and ongoing market share losses, indicating potential challenges in meeting future earnings expectations.